Lisa Maier
Concepts (618)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Berylliosis | 76 | 2024 | 187 | 14.840 |
Why?
| Beryllium | 60 | 2024 | 154 | 10.020 |
Why?
| Sarcoidosis | 40 | 2025 | 151 | 9.720 |
Why?
| Sarcoidosis, Pulmonary | 25 | 2025 | 74 | 6.550 |
Why?
| Occupational Exposure | 38 | 2024 | 313 | 6.250 |
Why?
| Occupational Diseases | 8 | 2024 | 143 | 2.550 |
Why?
| HLA-DP beta-Chains | 14 | 2024 | 84 | 2.290 |
Why?
| Chronic Disease | 49 | 2022 | 1717 | 1.840 |
Why?
| Lung Diseases | 10 | 2022 | 755 | 1.810 |
Why?
| Bronchoalveolar Lavage Fluid | 26 | 2024 | 642 | 1.600 |
Why?
| Polymorphism, Genetic | 13 | 2021 | 642 | 1.410 |
Why?
| Genetic Predisposition to Disease | 17 | 2024 | 2273 | 1.400 |
Why?
| Adrenal Cortex Hormones | 5 | 2020 | 525 | 1.270 |
Why?
| HLA-DP Antigens | 9 | 2011 | 32 | 1.180 |
Why?
| Lung | 32 | 2025 | 3925 | 1.150 |
Why?
| Lymphocytes | 13 | 2020 | 369 | 1.130 |
Why?
| CD4-Positive T-Lymphocytes | 19 | 2021 | 1044 | 1.100 |
Why?
| Humans | 161 | 2025 | 129078 | 1.080 |
Why?
| Biomarkers | 13 | 2024 | 3878 | 1.030 |
Why?
| Case-Control Studies | 24 | 2024 | 3336 | 1.020 |
Why?
| Middle Aged | 76 | 2025 | 31024 | 0.970 |
Why?
| Pulmonary Disease, Chronic Obstructive | 5 | 2022 | 985 | 0.940 |
Why?
| Leukocytes, Mononuclear | 8 | 2023 | 543 | 0.940 |
Why?
| Tumor Necrosis Factor-alpha | 14 | 2021 | 1204 | 0.890 |
Why?
| Granuloma | 7 | 2024 | 88 | 0.890 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2017 | 339 | 0.870 |
Why?
| Gene Expression Regulation | 6 | 2021 | 2523 | 0.850 |
Why?
| Alveolitis, Extrinsic Allergic | 6 | 2021 | 96 | 0.820 |
Why?
| Nicotine | 2 | 2021 | 303 | 0.810 |
Why?
| Tomography, X-Ray Computed | 8 | 2025 | 2530 | 0.810 |
Why?
| Lipopolysaccharide Receptors | 3 | 2015 | 90 | 0.800 |
Why?
| Skin Diseases | 2 | 2024 | 143 | 0.800 |
Why?
| Gene-Environment Interaction | 1 | 2023 | 185 | 0.780 |
Why?
| Environmental Exposure | 6 | 2022 | 479 | 0.770 |
Why?
| Male | 83 | 2025 | 63248 | 0.760 |
Why?
| Lymphocyte Activation | 18 | 2014 | 1094 | 0.720 |
Why?
| Alleles | 11 | 2023 | 847 | 0.710 |
Why?
| Female | 80 | 2025 | 68274 | 0.700 |
Why?
| Hypersensitivity | 6 | 2014 | 277 | 0.670 |
Why?
| Mesalamine | 2 | 2017 | 9 | 0.660 |
Why?
| Aged | 45 | 2021 | 22068 | 0.660 |
Why?
| HLA Antigens | 3 | 2015 | 236 | 0.660 |
Why?
| Genotype | 14 | 2024 | 1835 | 0.660 |
Why?
| Drug Interactions | 1 | 2021 | 370 | 0.650 |
Why?
| Adult | 58 | 2024 | 35423 | 0.640 |
Why?
| Biomedical Research | 4 | 2022 | 654 | 0.630 |
Why?
| Receptors, IgG | 2 | 2018 | 73 | 0.620 |
Why?
| Phenotype | 11 | 2023 | 3062 | 0.620 |
Why?
| Respiratory Hypersensitivity | 5 | 2012 | 64 | 0.610 |
Why?
| Disease Progression | 9 | 2024 | 2607 | 0.610 |
Why?
| Immunity, Cellular | 2 | 2017 | 267 | 0.590 |
Why?
| Microbiota | 4 | 2023 | 724 | 0.580 |
Why?
| Cytokines | 8 | 2019 | 1997 | 0.560 |
Why?
| Military Personnel | 1 | 2024 | 512 | 0.550 |
Why?
| Dyspnea | 2 | 2021 | 236 | 0.550 |
Why?
| Cough | 1 | 2018 | 118 | 0.540 |
Why?
| Gene Expression Profiling | 3 | 2021 | 1696 | 0.520 |
Why?
| Cell Proliferation | 13 | 2018 | 2344 | 0.520 |
Why?
| Proteins | 3 | 2020 | 945 | 0.510 |
Why?
| DNA Methylation | 3 | 2024 | 602 | 0.510 |
Why?
| alpha 1-Antitrypsin Deficiency | 3 | 2022 | 71 | 0.500 |
Why?
| Macrophages, Alveolar | 4 | 2020 | 389 | 0.500 |
Why?
| Pulmonary Diffusing Capacity | 3 | 2024 | 73 | 0.490 |
Why?
| Bronchoalveolar Lavage | 6 | 2022 | 92 | 0.480 |
Why?
| Asthma | 3 | 2020 | 2260 | 0.470 |
Why?
| Respiratory Function Tests | 8 | 2024 | 596 | 0.470 |
Why?
| Immunization | 4 | 2008 | 416 | 0.460 |
Why?
| Mycophenolic Acid | 1 | 2014 | 95 | 0.450 |
Why?
| Particle Size | 4 | 2014 | 351 | 0.440 |
Why?
| Severity of Illness Index | 11 | 2024 | 2768 | 0.440 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 268 | 0.440 |
Why?
| Radiography, Thoracic | 3 | 2024 | 162 | 0.430 |
Why?
| Immunity, Innate | 4 | 2022 | 804 | 0.430 |
Why?
| Models, Immunological | 3 | 2013 | 94 | 0.420 |
Why?
| Odds Ratio | 6 | 2020 | 1021 | 0.410 |
Why?
| Immunosuppressive Agents | 3 | 2024 | 699 | 0.400 |
Why?
| Allergens | 4 | 2012 | 463 | 0.400 |
Why?
| T-Lymphocytes | 4 | 2022 | 1913 | 0.400 |
Why?
| Cardiomyopathies | 5 | 2020 | 333 | 0.390 |
Why?
| Periodicals as Topic | 1 | 2015 | 209 | 0.390 |
Why?
| Air Pollutants, Occupational | 2 | 2010 | 36 | 0.380 |
Why?
| Dendritic Cells | 2 | 2014 | 478 | 0.380 |
Why?
| Glutamic Acid | 4 | 2007 | 231 | 0.370 |
Why?
| Diagnosis, Differential | 6 | 2024 | 1435 | 0.360 |
Why?
| Risk Factors | 14 | 2020 | 9804 | 0.360 |
Why?
| Medical Laboratory Personnel | 1 | 2010 | 7 | 0.350 |
Why?
| Quality of Life | 8 | 2024 | 2711 | 0.350 |
Why?
| Endotoxins | 2 | 2010 | 221 | 0.340 |
Why?
| Transcriptome | 4 | 2024 | 875 | 0.340 |
Why?
| Forced Expiratory Volume | 4 | 2018 | 509 | 0.340 |
Why?
| Pulmonary Emphysema | 2 | 2023 | 278 | 0.340 |
Why?
| Vital Capacity | 4 | 2019 | 285 | 0.340 |
Why?
| Antibodies, Monoclonal | 5 | 2012 | 1361 | 0.340 |
Why?
| Receptors, CCR5 | 1 | 2010 | 58 | 0.330 |
Why?
| Th1 Cells | 3 | 2013 | 135 | 0.320 |
Why?
| Lung Diseases, Interstitial | 2 | 2020 | 594 | 0.320 |
Why?
| Systems Biology | 2 | 2021 | 59 | 0.310 |
Why?
| Smoking | 6 | 2021 | 1501 | 0.310 |
Why?
| Interferon-gamma | 8 | 2021 | 759 | 0.300 |
Why?
| Aged, 80 and over | 15 | 2020 | 7063 | 0.300 |
Why?
| HLA-DR Antigens | 4 | 2015 | 226 | 0.300 |
Why?
| Exosomes | 2 | 2021 | 95 | 0.300 |
Why?
| Glutathione | 3 | 2017 | 333 | 0.300 |
Why?
| Logistic Models | 7 | 2020 | 1966 | 0.290 |
Why?
| Host-Pathogen Interactions | 3 | 2021 | 348 | 0.290 |
Why?
| RNA | 3 | 2023 | 877 | 0.290 |
Why?
| United States | 13 | 2022 | 13992 | 0.290 |
Why?
| Administration, Inhalation | 2 | 2020 | 675 | 0.280 |
Why?
| Pulmonary Fibrosis | 2 | 2020 | 381 | 0.280 |
Why?
| Bacteria | 3 | 2023 | 812 | 0.270 |
Why?
| Retrospective Studies | 9 | 2022 | 14562 | 0.260 |
Why?
| Epitopes, T-Lymphocyte | 3 | 2021 | 185 | 0.260 |
Why?
| Bronchoscopy | 5 | 2021 | 215 | 0.250 |
Why?
| Proteomics | 5 | 2022 | 988 | 0.250 |
Why?
| Spirometry | 2 | 2024 | 252 | 0.250 |
Why?
| Cause of Death | 2 | 2019 | 392 | 0.250 |
Why?
| Mortality | 2 | 2019 | 310 | 0.250 |
Why?
| T-Lymphocyte Subsets | 7 | 2013 | 411 | 0.240 |
Why?
| Membrane Glycoproteins | 1 | 2007 | 465 | 0.240 |
Why?
| Biopsy | 5 | 2020 | 1093 | 0.230 |
Why?
| Occupational Health | 2 | 2020 | 195 | 0.230 |
Why?
| Genetic Variation | 3 | 2023 | 935 | 0.230 |
Why?
| Genome-Wide Association Study | 5 | 2024 | 1334 | 0.230 |
Why?
| Central Nervous System Diseases | 2 | 2021 | 68 | 0.220 |
Why?
| Chemokine CX3CL1 | 1 | 2023 | 24 | 0.220 |
Why?
| Neopterin | 1 | 2003 | 12 | 0.220 |
Why?
| Metagenomics | 2 | 2023 | 153 | 0.210 |
Why?
| Genetic Association Studies | 2 | 2023 | 356 | 0.210 |
Why?
| Animals | 18 | 2023 | 34708 | 0.200 |
Why?
| Somatomedins | 1 | 2022 | 28 | 0.200 |
Why?
| Aerosols | 2 | 2020 | 172 | 0.200 |
Why?
| Double-Blind Method | 3 | 2017 | 1864 | 0.200 |
Why?
| Histocompatibility Antigens Class II | 1 | 2003 | 361 | 0.190 |
Why?
| Inhalation Exposure | 3 | 2020 | 111 | 0.190 |
Why?
| Duloxetine Hydrochloride | 1 | 2021 | 12 | 0.190 |
Why?
| Aspergillus nidulans | 1 | 2021 | 6 | 0.190 |
Why?
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2022 | 102 | 0.190 |
Why?
| Sputum | 2 | 2014 | 309 | 0.190 |
Why?
| Dust | 1 | 2022 | 100 | 0.190 |
Why?
| Nuclear Weapons | 2 | 2011 | 5 | 0.190 |
Why?
| Chemokine CCL3 | 1 | 2021 | 16 | 0.190 |
Why?
| Immunologic Tests | 1 | 2001 | 19 | 0.190 |
Why?
| Chemokine CCL4 | 1 | 2021 | 21 | 0.190 |
Why?
| Hydrogen Sulfide | 1 | 2001 | 41 | 0.180 |
Why?
| Silicon Dioxide | 1 | 2022 | 107 | 0.180 |
Why?
| T-Lymphocytes, Regulatory | 4 | 2021 | 377 | 0.180 |
Why?
| Salmonella typhimurium | 2 | 2013 | 174 | 0.180 |
Why?
| Societies | 1 | 2020 | 37 | 0.180 |
Why?
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 19 | 0.180 |
Why?
| Maximum Allowable Concentration | 1 | 2020 | 14 | 0.180 |
Why?
| Circulating MicroRNA | 1 | 2021 | 25 | 0.180 |
Why?
| Immunoglobulin G | 4 | 2022 | 837 | 0.180 |
Why?
| Mandibular Nerve | 1 | 2020 | 4 | 0.180 |
Why?
| Arthroplasty, Replacement | 1 | 2021 | 47 | 0.180 |
Why?
| Cluster Analysis | 1 | 2022 | 479 | 0.180 |
Why?
| Mandibular Fractures | 1 | 2020 | 11 | 0.170 |
Why?
| Image Processing, Computer-Assisted | 1 | 2025 | 740 | 0.170 |
Why?
| Longitudinal Studies | 5 | 2017 | 2670 | 0.170 |
Why?
| Cohort Studies | 3 | 2020 | 5400 | 0.170 |
Why?
| Communicable Diseases | 1 | 2022 | 141 | 0.170 |
Why?
| Mandible | 1 | 2020 | 64 | 0.170 |
Why?
| Smoke | 1 | 2021 | 142 | 0.170 |
Why?
| Extracellular Vesicles | 1 | 2022 | 123 | 0.170 |
Why?
| Interleukin-4 | 1 | 2001 | 214 | 0.170 |
Why?
| Unemployment | 1 | 2020 | 42 | 0.170 |
Why?
| Personal Protective Equipment | 1 | 2020 | 54 | 0.170 |
Why?
| B-Lymphocyte Subsets | 1 | 2020 | 75 | 0.170 |
Why?
| Macrophages | 3 | 2021 | 1456 | 0.170 |
Why?
| Sensitivity and Specificity | 5 | 2013 | 1842 | 0.170 |
Why?
| Masks | 1 | 2020 | 59 | 0.170 |
Why?
| Electrocardiography | 2 | 2020 | 603 | 0.160 |
Why?
| Propensity Score | 1 | 2020 | 262 | 0.160 |
Why?
| Electrophysiologic Techniques, Cardiac | 1 | 2019 | 75 | 0.160 |
Why?
| Peptidyl-Dipeptidase A | 1 | 1999 | 53 | 0.160 |
Why?
| Inflammation Mediators | 3 | 2012 | 503 | 0.160 |
Why?
| Kidney Diseases | 2 | 2020 | 366 | 0.160 |
Why?
| Income | 1 | 2020 | 191 | 0.160 |
Why?
| Pneumoconiosis | 1 | 2019 | 19 | 0.160 |
Why?
| Immunologic Memory | 4 | 2013 | 337 | 0.150 |
Why?
| Antioxidants | 2 | 2016 | 559 | 0.150 |
Why?
| Oxygen Inhalation Therapy | 1 | 2020 | 146 | 0.150 |
Why?
| Algorithms | 2 | 2020 | 1626 | 0.150 |
Why?
| Residual Volume | 1 | 2018 | 6 | 0.150 |
Why?
| Polymorphism, Single Nucleotide | 5 | 2024 | 2071 | 0.150 |
Why?
| Chemokines | 2 | 2019 | 227 | 0.150 |
Why?
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 326 | 0.150 |
Why?
| Immunologic Factors | 1 | 2020 | 227 | 0.150 |
Why?
| Gene Expression | 2 | 2021 | 1477 | 0.140 |
Why?
| Cost of Illness | 1 | 2020 | 290 | 0.140 |
Why?
| Cellular Senescence | 1 | 2019 | 176 | 0.140 |
Why?
| September 11 Terrorist Attacks | 1 | 2017 | 30 | 0.140 |
Why?
| Clinical Laboratory Techniques | 1 | 2018 | 86 | 0.140 |
Why?
| Dental Technicians | 2 | 2014 | 3 | 0.140 |
Why?
| Magnetic Resonance Imaging | 3 | 2020 | 3357 | 0.140 |
Why?
| Pilot Projects | 2 | 2020 | 1548 | 0.140 |
Why?
| Regression Analysis | 2 | 2019 | 987 | 0.140 |
Why?
| Betacoronavirus | 1 | 2020 | 266 | 0.140 |
Why?
| Monocytes | 2 | 2023 | 553 | 0.140 |
Why?
| Liver Diseases | 1 | 2020 | 284 | 0.140 |
Why?
| Air Pollutants | 1 | 2001 | 323 | 0.140 |
Why?
| Arthritis, Juvenile | 1 | 2017 | 54 | 0.140 |
Why?
| Clinical Decision-Making | 1 | 2020 | 311 | 0.140 |
Why?
| Firefighters | 1 | 2017 | 39 | 0.140 |
Why?
| Ventricular Function, Right | 1 | 2019 | 274 | 0.140 |
Why?
| Global Health | 2 | 2018 | 317 | 0.140 |
Why?
| Arrhythmias, Cardiac | 1 | 2019 | 313 | 0.130 |
Why?
| HLA-DQ Antigens | 2 | 2010 | 180 | 0.130 |
Why?
| Biological Products | 1 | 2020 | 202 | 0.130 |
Why?
| Promoter Regions, Genetic | 3 | 2019 | 1195 | 0.130 |
Why?
| Congresses as Topic | 1 | 2018 | 217 | 0.130 |
Why?
| Positron-Emission Tomography | 2 | 2020 | 285 | 0.130 |
Why?
| Genome, Human | 1 | 2019 | 393 | 0.130 |
Why?
| Lung Injury | 1 | 2019 | 214 | 0.130 |
Why?
| Disease Management | 1 | 2020 | 594 | 0.130 |
Why?
| Banking, Personal | 1 | 2016 | 3 | 0.130 |
Why?
| Mass Screening | 2 | 2018 | 1129 | 0.130 |
Why?
| Predictive Value of Tests | 5 | 2019 | 1968 | 0.130 |
Why?
| Action Potentials | 1 | 2019 | 464 | 0.130 |
Why?
| Decision Support Techniques | 1 | 2020 | 387 | 0.130 |
Why?
| Deoxyguanosine | 1 | 2016 | 27 | 0.130 |
Why?
| Mice | 9 | 2023 | 16583 | 0.130 |
Why?
| Health Care Sector | 1 | 2016 | 25 | 0.130 |
Why?
| Death Certificates | 1 | 2016 | 31 | 0.130 |
Why?
| Poisson Distribution | 1 | 2016 | 75 | 0.130 |
Why?
| Exercise Tolerance | 1 | 2018 | 266 | 0.130 |
Why?
| HLA-DRB1 Chains | 3 | 2023 | 107 | 0.130 |
Why?
| MicroRNAs | 2 | 2024 | 669 | 0.130 |
Why?
| Ventricular Function, Left | 1 | 2019 | 526 | 0.130 |
Why?
| Adaptive Immunity | 2 | 2019 | 161 | 0.120 |
Why?
| Transcription, Genetic | 2 | 2016 | 1409 | 0.120 |
Why?
| Commerce | 1 | 2016 | 69 | 0.120 |
Why?
| Pandemics | 2 | 2022 | 1516 | 0.120 |
Why?
| Drug Administration Schedule | 2 | 2014 | 760 | 0.120 |
Why?
| Heart Rate | 1 | 2019 | 808 | 0.120 |
Why?
| Pneumonia, Viral | 1 | 2020 | 361 | 0.120 |
Why?
| International Classification of Diseases | 1 | 2016 | 124 | 0.120 |
Why?
| Coronavirus Infections | 1 | 2020 | 355 | 0.120 |
Why?
| Acetylcysteine | 1 | 2016 | 148 | 0.120 |
Why?
| Patch Tests | 3 | 2021 | 56 | 0.120 |
Why?
| Disease Models, Animal | 3 | 2021 | 3999 | 0.120 |
Why?
| Metals | 1 | 2016 | 126 | 0.120 |
Why?
| Salmonella Infections | 2 | 2013 | 54 | 0.120 |
Why?
| Drug Evaluation | 1 | 2014 | 79 | 0.120 |
Why?
| Granulomatous Disease, Chronic | 1 | 2014 | 53 | 0.120 |
Why?
| Glucocorticoids | 2 | 2020 | 571 | 0.120 |
Why?
| Environmental Monitoring | 2 | 2014 | 333 | 0.110 |
Why?
| Cells, Cultured | 7 | 2013 | 4063 | 0.110 |
Why?
| Adolescent | 9 | 2020 | 20241 | 0.110 |
Why?
| Young Adult | 8 | 2020 | 12310 | 0.110 |
Why?
| Population Surveillance | 3 | 2009 | 428 | 0.110 |
Why?
| Metallurgy | 1 | 2014 | 9 | 0.110 |
Why?
| Apoptosis | 4 | 2005 | 2485 | 0.110 |
Why?
| Haplotypes | 4 | 2010 | 473 | 0.110 |
Why?
| CD40 Antigens | 1 | 2014 | 88 | 0.110 |
Why?
| Israel | 1 | 2014 | 47 | 0.110 |
Why?
| Colorado | 4 | 2020 | 4445 | 0.110 |
Why?
| Heart Diseases | 1 | 2017 | 356 | 0.110 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 772 | 0.110 |
Why?
| Gastrointestinal Microbiome | 1 | 2021 | 635 | 0.110 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2014 | 332 | 0.110 |
Why?
| B-Lymphocytes | 1 | 2019 | 813 | 0.110 |
Why?
| Oxidative Stress | 3 | 2016 | 1221 | 0.110 |
Why?
| Teaching | 1 | 2016 | 210 | 0.110 |
Why?
| Prednisone | 1 | 2014 | 241 | 0.110 |
Why?
| Genetic Markers | 3 | 2021 | 336 | 0.110 |
Why?
| Imidazoles | 1 | 2014 | 225 | 0.110 |
Why?
| Myocardial Infarction | 1 | 2021 | 1031 | 0.110 |
Why?
| Occupational Health Services | 1 | 2013 | 32 | 0.110 |
Why?
| Phagocytosis | 1 | 2015 | 363 | 0.100 |
Why?
| CTLA-4 Antigen | 1 | 2013 | 88 | 0.100 |
Why?
| Pulmonary Gas Exchange | 2 | 2004 | 119 | 0.100 |
Why?
| Nickel | 1 | 2013 | 53 | 0.100 |
Why?
| Enzyme Activation | 1 | 2014 | 811 | 0.100 |
Why?
| MAP Kinase Signaling System | 1 | 2014 | 305 | 0.100 |
Why?
| Radiopharmaceuticals | 1 | 2013 | 167 | 0.100 |
Why?
| o-Phthalaldehyde | 1 | 2012 | 3 | 0.100 |
Why?
| Fluorodeoxyglucose F18 | 1 | 2013 | 127 | 0.100 |
Why?
| NF-kappa B | 2 | 2014 | 687 | 0.100 |
Why?
| Static Electricity | 1 | 2012 | 116 | 0.100 |
Why?
| Dermatitis, Allergic Contact | 1 | 2013 | 70 | 0.100 |
Why?
| Linkage Disequilibrium | 2 | 2010 | 255 | 0.100 |
Why?
| Infliximab | 1 | 2012 | 102 | 0.100 |
Why?
| Industry | 2 | 2011 | 64 | 0.100 |
Why?
| Ceftriaxone | 1 | 2012 | 19 | 0.100 |
Why?
| Idiopathic Pulmonary Fibrosis | 1 | 2019 | 619 | 0.100 |
Why?
| Ciprofloxacin | 1 | 2012 | 30 | 0.100 |
Why?
| Treatment Outcome | 5 | 2024 | 10256 | 0.100 |
Why?
| Metabolomics | 3 | 2023 | 594 | 0.100 |
Why?
| Risk Assessment | 4 | 2020 | 3290 | 0.100 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 163 | 0.090 |
Why?
| Surveys and Questionnaires | 4 | 2021 | 5365 | 0.090 |
Why?
| Psoriasis | 1 | 2012 | 90 | 0.090 |
Why?
| Epidermis | 1 | 2012 | 156 | 0.090 |
Why?
| Amino Acid Substitution | 1 | 2012 | 283 | 0.090 |
Why?
| Drug Therapy, Combination | 1 | 2014 | 1020 | 0.090 |
Why?
| DNA | 3 | 2016 | 1407 | 0.090 |
Why?
| Receptors, Cell Surface | 3 | 2020 | 379 | 0.090 |
Why?
| Polymerase Chain Reaction | 2 | 2011 | 1045 | 0.090 |
Why?
| Gene Frequency | 3 | 2010 | 503 | 0.090 |
Why?
| Pyridines | 1 | 2014 | 472 | 0.090 |
Why?
| Diarrhea | 1 | 2012 | 179 | 0.090 |
Why?
| Forced Expiratory Flow Rates | 1 | 2010 | 15 | 0.090 |
Why?
| Cell Division | 6 | 2013 | 802 | 0.090 |
Why?
| Endocytosis | 1 | 1991 | 162 | 0.090 |
Why?
| fas Receptor | 2 | 2008 | 96 | 0.090 |
Why?
| Interleukins | 1 | 2012 | 245 | 0.090 |
Why?
| Genes, MHC Class II | 1 | 2010 | 72 | 0.090 |
Why?
| Hospitalization | 1 | 2020 | 2080 | 0.090 |
Why?
| Occupations | 2 | 2019 | 42 | 0.090 |
Why?
| Phosphorylation | 1 | 2014 | 1686 | 0.080 |
Why?
| Prognosis | 3 | 2021 | 3793 | 0.080 |
Why?
| Sex Factors | 1 | 2016 | 1950 | 0.080 |
Why?
| Diagnostic Errors | 1 | 2011 | 163 | 0.080 |
Why?
| Sulfasalazine | 1 | 2009 | 23 | 0.080 |
Why?
| Up-Regulation | 3 | 2008 | 850 | 0.080 |
Why?
| Antigens | 2 | 2021 | 348 | 0.080 |
Why?
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2009 | 28 | 0.080 |
Why?
| Research Design | 1 | 2015 | 1039 | 0.080 |
Why?
| Exercise Test | 2 | 2003 | 619 | 0.080 |
Why?
| Uveitis | 1 | 2010 | 128 | 0.080 |
Why?
| Biological Evolution | 1 | 2013 | 428 | 0.080 |
Why?
| Lipopolysaccharides | 3 | 2023 | 877 | 0.080 |
Why?
| Homozygote | 2 | 2007 | 192 | 0.080 |
Why?
| Animals, Laboratory | 1 | 2008 | 17 | 0.080 |
Why?
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2008 | 25 | 0.080 |
Why?
| Inflammation | 5 | 2023 | 2696 | 0.080 |
Why?
| Multivariate Analysis | 3 | 2020 | 1504 | 0.080 |
Why?
| HLA-D Antigens | 1 | 2008 | 34 | 0.070 |
Why?
| Time Factors | 3 | 2019 | 6579 | 0.070 |
Why?
| Butyrophilins | 1 | 2007 | 6 | 0.070 |
Why?
| Eye Diseases | 2 | 2020 | 78 | 0.070 |
Why?
| Proto-Oncogene Proteins | 1 | 1991 | 638 | 0.070 |
Why?
| Antigen Presentation | 2 | 2005 | 205 | 0.070 |
Why?
| CD57 Antigens | 1 | 2007 | 16 | 0.070 |
Why?
| Antigens, CD | 2 | 2008 | 480 | 0.070 |
Why?
| Prevalence | 2 | 2011 | 2541 | 0.070 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2008 | 181 | 0.070 |
Why?
| Fatal Outcome | 1 | 2008 | 301 | 0.070 |
Why?
| Transforming Growth Factor beta1 | 1 | 2007 | 162 | 0.070 |
Why?
| Glutamate-Cysteine Ligase | 1 | 2006 | 18 | 0.070 |
Why?
| Total Lung Capacity | 1 | 2006 | 33 | 0.070 |
Why?
| Flow Cytometry | 3 | 2023 | 1147 | 0.070 |
Why?
| Protein Binding | 1 | 2012 | 2087 | 0.070 |
Why?
| Toll-Like Receptor 4 | 1 | 2008 | 294 | 0.060 |
Why?
| Reactive Oxygen Species | 2 | 2008 | 578 | 0.060 |
Why?
| B7-2 Antigen | 2 | 2017 | 26 | 0.060 |
Why?
| Cell Line | 5 | 2013 | 2762 | 0.060 |
Why?
| Cell Separation | 2 | 2023 | 312 | 0.060 |
Why?
| Chemical Industry | 1 | 2005 | 11 | 0.060 |
Why?
| Mice, Transgenic | 2 | 2021 | 2082 | 0.060 |
Why?
| Biomarkers, Tumor | 1 | 1991 | 1174 | 0.060 |
Why?
| Nuclear Warfare | 1 | 2004 | 6 | 0.060 |
Why?
| Protein Structure, Secondary | 1 | 2005 | 335 | 0.060 |
Why?
| Reproducibility of Results | 3 | 2021 | 3047 | 0.060 |
Why?
| Follow-Up Studies | 2 | 2017 | 4927 | 0.060 |
Why?
| Ferritins | 1 | 2004 | 58 | 0.060 |
Why?
| Genomics | 2 | 2022 | 716 | 0.060 |
Why?
| HLA-DRB3 Chains | 1 | 2003 | 2 | 0.060 |
Why?
| HLA-DRB5 Chains | 1 | 2003 | 2 | 0.060 |
Why?
| HLA-DRB4 Chains | 1 | 2003 | 6 | 0.060 |
Why?
| CX3C Chemokine Receptor 1 | 1 | 2023 | 21 | 0.060 |
Why?
| HLA-DR alpha-Chains | 1 | 2023 | 4 | 0.050 |
Why?
| HLA-DQ beta-Chains | 1 | 2003 | 62 | 0.050 |
Why?
| Decision Making | 1 | 2010 | 837 | 0.050 |
Why?
| Societies, Medical | 2 | 2020 | 760 | 0.050 |
Why?
| Endothelium | 1 | 2023 | 115 | 0.050 |
Why?
| RNA, Messenger | 3 | 2024 | 2702 | 0.050 |
Why?
| Reference Standards | 1 | 2023 | 169 | 0.050 |
Why?
| Thorax | 1 | 2022 | 41 | 0.050 |
Why?
| Aluminum | 1 | 2002 | 38 | 0.050 |
Why?
| Cobalt | 1 | 2002 | 52 | 0.050 |
Why?
| Granuloma, Respiratory Tract | 1 | 2002 | 11 | 0.050 |
Why?
| Immunity, Active | 1 | 2002 | 10 | 0.050 |
Why?
| alpha 1-Antitrypsin | 1 | 2023 | 111 | 0.050 |
Why?
| Myosins | 1 | 2022 | 133 | 0.050 |
Why?
| DNA Probes, HLA | 1 | 2001 | 1 | 0.050 |
Why?
| Cell Communication | 1 | 2023 | 293 | 0.050 |
Why?
| Administration, Oral | 2 | 2016 | 784 | 0.050 |
Why?
| Epitopes | 1 | 2003 | 469 | 0.050 |
Why?
| Antigens, Fungal | 1 | 2021 | 26 | 0.050 |
Why?
| Cells | 1 | 2021 | 24 | 0.050 |
Why?
| Ligands | 1 | 2023 | 616 | 0.050 |
Why?
| Eosinophil Cationic Protein | 1 | 2021 | 9 | 0.050 |
Why?
| Enzyme-Linked Immunospot Assay | 2 | 2011 | 35 | 0.050 |
Why?
| Mining | 1 | 2001 | 17 | 0.050 |
Why?
| Oxygen Consumption | 1 | 2004 | 676 | 0.050 |
Why?
| HLA-DR3 Antigen | 1 | 2021 | 81 | 0.050 |
Why?
| Bronchiolitis | 1 | 2002 | 92 | 0.050 |
Why?
| CD55 Antigens | 1 | 2021 | 26 | 0.050 |
Why?
| CD28 Antigens | 2 | 2013 | 48 | 0.050 |
Why?
| Hybridomas | 1 | 2021 | 234 | 0.050 |
Why?
| Chemokine CXCL9 | 1 | 2021 | 23 | 0.050 |
Why?
| Minimal Clinically Important Difference | 1 | 2021 | 14 | 0.050 |
Why?
| Immunoglobulin M | 1 | 2022 | 268 | 0.050 |
Why?
| Observational Studies as Topic | 1 | 2021 | 108 | 0.050 |
Why?
| Click Chemistry | 1 | 2021 | 48 | 0.050 |
Why?
| Th17 Cells | 1 | 2021 | 81 | 0.040 |
Why?
| RNA, Ribosomal, 16S | 1 | 2023 | 521 | 0.040 |
Why?
| Fungal Proteins | 1 | 2021 | 129 | 0.040 |
Why?
| Bone Cements | 1 | 2021 | 44 | 0.040 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 822 | 0.040 |
Why?
| Chi-Square Distribution | 3 | 2011 | 513 | 0.040 |
Why?
| Trigeminal Nerve Injuries | 1 | 2020 | 2 | 0.040 |
Why?
| Biomedical Engineering | 1 | 2020 | 24 | 0.040 |
Why?
| CD11c Antigen | 1 | 2020 | 40 | 0.040 |
Why?
| Radiography | 1 | 2003 | 864 | 0.040 |
Why?
| Serologic Tests | 1 | 2020 | 49 | 0.040 |
Why?
| Mice, Inbred C57BL | 3 | 2019 | 5282 | 0.040 |
Why?
| Multicenter Studies as Topic | 1 | 2021 | 288 | 0.040 |
Why?
| Pharmaceutical Preparations | 1 | 2022 | 171 | 0.040 |
Why?
| Fatigue Syndrome, Chronic | 1 | 2020 | 15 | 0.040 |
Why?
| Lymphadenopathy | 1 | 2020 | 8 | 0.040 |
Why?
| Mediastinum | 1 | 2020 | 23 | 0.040 |
Why?
| Textiles | 1 | 2020 | 22 | 0.040 |
Why?
| Hypercalcemia | 1 | 2020 | 21 | 0.040 |
Why?
| Communicable Disease Control | 1 | 2020 | 72 | 0.040 |
Why?
| Receptors, Fc | 1 | 2020 | 49 | 0.040 |
Why?
| Self-Help Devices | 1 | 2020 | 19 | 0.040 |
Why?
| Medical History Taking | 1 | 2020 | 119 | 0.040 |
Why?
| Intersectoral Collaboration | 1 | 2020 | 61 | 0.040 |
Why?
| T-Box Domain Proteins | 1 | 2020 | 96 | 0.040 |
Why?
| Electrocardiography, Ambulatory | 1 | 2020 | 58 | 0.040 |
Why?
| Aspartate Aminotransferases | 1 | 2020 | 86 | 0.040 |
Why?
| Cryosurgery | 1 | 2020 | 54 | 0.040 |
Why?
| Radionuclide Imaging | 1 | 2019 | 126 | 0.040 |
Why?
| Fractals | 1 | 2019 | 8 | 0.040 |
Why?
| Prostheses and Implants | 1 | 2021 | 140 | 0.040 |
Why?
| Mobility Limitation | 1 | 2020 | 62 | 0.040 |
Why?
| Autoantigens | 1 | 2022 | 414 | 0.040 |
Why?
| Receptors, Complement 3d | 1 | 2020 | 140 | 0.040 |
Why?
| Models, Animal | 1 | 2021 | 371 | 0.040 |
Why?
| Prospective Studies | 2 | 2022 | 7070 | 0.040 |
Why?
| Amino Acid Sequence | 3 | 2013 | 2050 | 0.040 |
Why?
| Antidepressive Agents | 1 | 2021 | 226 | 0.040 |
Why?
| Tertiary Lymphoid Structures | 1 | 2019 | 6 | 0.040 |
Why?
| Chemokine CXCL13 | 1 | 2019 | 7 | 0.040 |
Why?
| Alanine Transaminase | 1 | 2020 | 147 | 0.040 |
Why?
| Alkaline Phosphatase | 1 | 2020 | 148 | 0.040 |
Why?
| Pulmonary Surfactant-Associated Protein A | 1 | 2019 | 34 | 0.040 |
Why?
| Pulmonary Medicine | 1 | 2020 | 79 | 0.040 |
Why?
| Breast Neoplasms | 1 | 1991 | 2116 | 0.040 |
Why?
| Receptors, Immunologic | 1 | 2020 | 213 | 0.040 |
Why?
| Pulmonary Surfactant-Associated Protein C | 1 | 2019 | 45 | 0.040 |
Why?
| GTPase-Activating Proteins | 1 | 2019 | 82 | 0.040 |
Why?
| Systole | 1 | 2019 | 190 | 0.040 |
Why?
| Exoribonucleases | 1 | 2019 | 43 | 0.040 |
Why?
| Sequence Analysis, RNA | 1 | 2021 | 422 | 0.040 |
Why?
| Mass Spectrometry | 1 | 2022 | 662 | 0.040 |
Why?
| Programmed Cell Death 1 Receptor | 2 | 2013 | 225 | 0.040 |
Why?
| Electric Countershock | 1 | 2019 | 105 | 0.040 |
Why?
| Endosonography | 1 | 2020 | 141 | 0.040 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2019 | 128 | 0.040 |
Why?
| Delphi Technique | 1 | 2020 | 220 | 0.040 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2019 | 98 | 0.040 |
Why?
| Reoperation | 1 | 2021 | 556 | 0.040 |
Why?
| Interleukin-2 | 2 | 2013 | 428 | 0.040 |
Why?
| Confidence Intervals | 1 | 1999 | 318 | 0.040 |
Why?
| Endothelial Cells | 1 | 2023 | 737 | 0.040 |
Why?
| Creatinine | 1 | 2020 | 486 | 0.040 |
Why?
| Telomere-Binding Proteins | 1 | 2019 | 102 | 0.040 |
Why?
| Receptor, Parathyroid Hormone, Type 1 | 1 | 2017 | 3 | 0.040 |
Why?
| Caenorhabditis elegans | 1 | 2021 | 301 | 0.040 |
Why?
| Death, Sudden, Cardiac | 1 | 2019 | 179 | 0.040 |
Why?
| Clinical Trials as Topic | 1 | 2002 | 1005 | 0.040 |
Why?
| DNA Helicases | 1 | 2019 | 149 | 0.040 |
Why?
| Janus Kinase 1 | 1 | 2017 | 24 | 0.040 |
Why?
| New York City | 1 | 2017 | 81 | 0.040 |
Why?
| High Mobility Group Proteins | 1 | 2017 | 42 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 3 | 2004 | 1974 | 0.040 |
Why?
| Adaptor Proteins, Vesicular Transport | 1 | 2017 | 45 | 0.040 |
Why?
| Lymph Nodes | 1 | 2020 | 459 | 0.040 |
Why?
| Forecasting | 1 | 2019 | 363 | 0.030 |
Why?
| RNA Splicing Factors | 1 | 2017 | 50 | 0.030 |
Why?
| Cross-Sectional Studies | 2 | 2011 | 5036 | 0.030 |
Why?
| Epigenomics | 1 | 2017 | 111 | 0.030 |
Why?
| Mucin-5B | 1 | 2019 | 217 | 0.030 |
Why?
| Telomerase | 1 | 2019 | 229 | 0.030 |
Why?
| Echocardiography | 1 | 2020 | 634 | 0.030 |
Why?
| Sleep Wake Disorders | 1 | 2020 | 246 | 0.030 |
Why?
| Consensus | 1 | 2020 | 646 | 0.030 |
Why?
| Base Sequence | 2 | 2014 | 2157 | 0.030 |
Why?
| Vitamin D | 1 | 2020 | 384 | 0.030 |
Why?
| Epigenesis, Genetic | 1 | 2021 | 613 | 0.030 |
Why?
| Poverty | 1 | 2020 | 492 | 0.030 |
Why?
| Sleep Apnea, Obstructive | 1 | 2020 | 238 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 2019 | 778 | 0.030 |
Why?
| Stroke Volume | 1 | 2019 | 587 | 0.030 |
Why?
| Defibrillators, Implantable | 1 | 2019 | 295 | 0.030 |
Why?
| Brain Diseases | 1 | 1997 | 133 | 0.030 |
Why?
| Chronic Pain | 1 | 2020 | 248 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 485 | 0.030 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2017 | 200 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2020 | 1192 | 0.030 |
Why?
| Hospitals | 1 | 2020 | 628 | 0.030 |
Why?
| Linear Models | 1 | 2018 | 818 | 0.030 |
Why?
| Mitochondrial Proteins | 1 | 2017 | 235 | 0.030 |
Why?
| Quantitative Trait Loci | 1 | 2017 | 355 | 0.030 |
Why?
| Comorbidity | 1 | 2020 | 1542 | 0.030 |
Why?
| Software | 1 | 2019 | 612 | 0.030 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 395 | 0.030 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 422 | 0.030 |
Why?
| Autoantibodies | 1 | 2022 | 1464 | 0.030 |
Why?
| Molecular Sequence Data | 2 | 2014 | 2846 | 0.030 |
Why?
| Repressor Proteins | 1 | 2017 | 400 | 0.030 |
Why?
| Membrane Proteins | 1 | 2020 | 1102 | 0.030 |
Why?
| Health Personnel | 1 | 2020 | 643 | 0.030 |
Why?
| Protective Devices | 1 | 2014 | 30 | 0.030 |
Why?
| Calcium | 1 | 2020 | 1175 | 0.030 |
Why?
| Heme Oxygenase-1 | 1 | 2014 | 62 | 0.030 |
Why?
| United States Occupational Safety and Health Administration | 1 | 2013 | 8 | 0.030 |
Why?
| B7-1 Antigen | 1 | 2013 | 59 | 0.030 |
Why?
| Hematologic Tests | 1 | 2013 | 23 | 0.030 |
Why?
| Cardiac Imaging Techniques | 1 | 2013 | 21 | 0.030 |
Why?
| Lymphokines | 1 | 2013 | 126 | 0.030 |
Why?
| Peptide Library | 1 | 2013 | 87 | 0.030 |
Why?
| Etanercept | 1 | 2012 | 58 | 0.020 |
Why?
| Mice, Knockout | 1 | 2019 | 2774 | 0.020 |
Why?
| Infusions, Parenteral | 1 | 2012 | 39 | 0.020 |
Why?
| Oxidation-Reduction | 1 | 2016 | 1014 | 0.020 |
Why?
| Interdisciplinary Communication | 1 | 2013 | 189 | 0.020 |
Why?
| Colony Count, Microbial | 1 | 2012 | 117 | 0.020 |
Why?
| Virulence | 1 | 2013 | 253 | 0.020 |
Why?
| Phagocytes | 2 | 2004 | 95 | 0.020 |
Why?
| Hyperplasia | 1 | 2012 | 171 | 0.020 |
Why?
| Microscopy, Immunoelectron | 1 | 1991 | 43 | 0.020 |
Why?
| Immunotoxins | 1 | 1991 | 45 | 0.020 |
Why?
| Virulence Factors | 1 | 2013 | 151 | 0.020 |
Why?
| Depression | 1 | 2020 | 1290 | 0.020 |
Why?
| Self Report | 1 | 2015 | 797 | 0.020 |
Why?
| Ontario | 1 | 2011 | 89 | 0.020 |
Why?
| Body Mass Index | 1 | 2019 | 2250 | 0.020 |
Why?
| Hypertension | 1 | 2020 | 1237 | 0.020 |
Why?
| Program Development | 1 | 2013 | 362 | 0.020 |
Why?
| Needs Assessment | 1 | 2013 | 360 | 0.020 |
Why?
| Educational Measurement | 1 | 2013 | 260 | 0.020 |
Why?
| Keratinocytes | 1 | 2012 | 240 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2011 | 392 | 0.020 |
Why?
| Gold | 1 | 1991 | 116 | 0.020 |
Why?
| Regeneration | 1 | 2012 | 178 | 0.020 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 136 | 0.020 |
Why?
| Netherlands | 1 | 2010 | 78 | 0.020 |
Why?
| Plasmids | 1 | 1991 | 358 | 0.020 |
Why?
| Japan | 1 | 2010 | 100 | 0.020 |
Why?
| Chromosome Mapping | 1 | 1991 | 505 | 0.020 |
Why?
| Risk | 2 | 2004 | 867 | 0.020 |
Why?
| Binding Sites | 1 | 2013 | 1239 | 0.020 |
Why?
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 76 | 0.020 |
Why?
| CD3 Complex | 1 | 2010 | 100 | 0.020 |
Why?
| Down-Regulation | 1 | 2012 | 639 | 0.020 |
Why?
| United Kingdom | 1 | 2010 | 264 | 0.020 |
Why?
| Intestines | 1 | 2013 | 347 | 0.020 |
Why?
| Antigen-Presenting Cells | 1 | 2009 | 151 | 0.020 |
Why?
| Transfection | 1 | 1991 | 907 | 0.020 |
Why?
| Receptor, ErbB-2 | 1 | 1991 | 334 | 0.020 |
Why?
| Forkhead Transcription Factors | 1 | 2010 | 182 | 0.020 |
Why?
| Blood Proteins | 1 | 2011 | 233 | 0.020 |
Why?
| Feces | 1 | 2012 | 430 | 0.020 |
Why?
| 4-1BB Ligand | 1 | 2008 | 7 | 0.020 |
Why?
| Program Evaluation | 1 | 2013 | 871 | 0.020 |
Why?
| Demography | 1 | 2009 | 280 | 0.020 |
Why?
| Hypertension, Pulmonary | 1 | 2020 | 1878 | 0.020 |
Why?
| Analysis of Variance | 1 | 2011 | 1285 | 0.020 |
Why?
| Immunophenotyping | 1 | 2009 | 311 | 0.020 |
Why?
| Peptides | 1 | 2013 | 904 | 0.020 |
Why?
| Codon | 1 | 2007 | 88 | 0.020 |
Why?
| Adjuvants, Immunologic | 1 | 2008 | 219 | 0.020 |
Why?
| Obesity | 1 | 2020 | 2847 | 0.020 |
Why?
| Fibrosis | 1 | 2009 | 518 | 0.020 |
Why?
| Fibroblasts | 1 | 1991 | 946 | 0.020 |
Why?
| Cell Survival | 1 | 2009 | 1085 | 0.020 |
Why?
| Transcription Factor AP-1 | 1 | 2006 | 85 | 0.020 |
Why?
| Gene Dosage | 1 | 2006 | 143 | 0.020 |
Why?
| RNA Precursors | 1 | 2006 | 140 | 0.020 |
Why?
| DNA, Complementary | 1 | 2005 | 270 | 0.020 |
Why?
| Caspase 8 | 1 | 2005 | 48 | 0.020 |
Why?
| Catalytic Domain | 1 | 2006 | 217 | 0.020 |
Why?
| Free Radical Scavengers | 1 | 2005 | 81 | 0.010 |
Why?
| Lymphocyte Count | 1 | 2005 | 149 | 0.010 |
Why?
| Models, Theoretical | 1 | 2008 | 550 | 0.010 |
Why?
| Mutagenesis, Site-Directed | 1 | 2005 | 357 | 0.010 |
Why?
| Radioisotopes | 1 | 2004 | 31 | 0.010 |
Why?
| Metalloporphyrins | 1 | 2005 | 106 | 0.010 |
Why?
| Caspases | 1 | 2005 | 248 | 0.010 |
Why?
| Species Specificity | 1 | 2005 | 568 | 0.010 |
Why?
| In Vitro Techniques | 1 | 2005 | 1061 | 0.010 |
Why?
| Infant | 1 | 2017 | 8997 | 0.010 |
Why?
| Rats | 1 | 1991 | 5254 | 0.010 |
Why?
| Child, Preschool | 1 | 2017 | 10462 | 0.010 |
Why?
| Kinetics | 1 | 2006 | 1622 | 0.010 |
Why?
| Genes, T-Cell Receptor beta | 1 | 2002 | 21 | 0.010 |
Why?
| In Situ Nick-End Labeling | 1 | 2002 | 126 | 0.010 |
Why?
| Mutation | 1 | 2013 | 3679 | 0.010 |
Why?
| Nuclear Proteins | 1 | 2006 | 644 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 2012 | 1702 | 0.010 |
Why?
| Biopsy, Needle | 1 | 2002 | 192 | 0.010 |
Why?
| Incidence | 1 | 2008 | 2635 | 0.010 |
Why?
| Utah | 1 | 2001 | 64 | 0.010 |
Why?
| Oximetry | 1 | 2001 | 86 | 0.010 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2000 | 87 | 0.010 |
Why?
| Tetanus Toxoid | 1 | 2000 | 37 | 0.010 |
Why?
| Bromodeoxyuridine | 1 | 2000 | 77 | 0.010 |
Why?
| Lectins, C-Type | 1 | 2000 | 69 | 0.010 |
Why?
| Volatilization | 1 | 2000 | 52 | 0.010 |
Why?
| Scattering, Radiation | 1 | 2000 | 98 | 0.010 |
Why?
| HLA-DP alpha-Chains | 1 | 1999 | 4 | 0.010 |
Why?
| Genetic Carrier Screening | 1 | 1999 | 25 | 0.010 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2004 | 703 | 0.010 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 2000 | 137 | 0.010 |
Why?
| Dimerization | 1 | 1999 | 189 | 0.010 |
Why?
| Acute Disease | 1 | 2002 | 978 | 0.010 |
Why?
| Transcription Factors | 1 | 2006 | 1636 | 0.010 |
Why?
| Fluorescent Dyes | 1 | 2000 | 319 | 0.010 |
Why?
| Equipment Design | 1 | 2000 | 523 | 0.010 |
Why?
| Child | 1 | 2017 | 20860 | 0.010 |
Why?
| Cell Movement | 1 | 2002 | 935 | 0.010 |
Why?
| Light | 1 | 2000 | 355 | 0.010 |
Why?
| Skin | 1 | 2002 | 737 | 0.010 |
Why?
| Oxygen | 1 | 2001 | 913 | 0.010 |
Why?
|
|
Maier's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|